Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$16.89
+5.7%
$14.48
$8.03
$17.75
$2.03B1.841.80 million shs2.01 million shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$37.50
-0.6%
$37.86
$27.34
$59.62
$6.89B0.261.13 million shs869,003 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$36.32
+0.8%
$37.93
$29.17
$62.40
$6.79B1.161.85 million shs1.39 million shs
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$97.61
+1.2%
$78.46
$43.57
$99.04
$6.48B2.38579,718 shs522,257 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.00%+14.35%+15.13%+15.37%+98.94%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.00%+1.35%-9.83%+28.82%-34.08%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.00%+3.77%-5.17%-9.04%-15.24%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
0.00%+6.12%+9.43%+59.36%+111.83%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
1.6344 of 5 stars
2.42.00.00.02.81.70.6
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
3.7243 of 5 stars
4.54.00.00.02.41.70.6
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.1709 of 5 stars
4.51.00.04.72.01.70.0
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.7387 of 5 stars
2.53.00.04.33.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.86
Moderate Buy$19.8017.23% Upside
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
3.00
Buy$72.3893.00% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$68.6789.06% Upside
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
3.07
Buy$101.574.06% Upside

Current Analyst Ratings Breakdown

Latest ARQT, LEGN, RVMD, and RYTM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$67.00
8/12/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$75.00 ➝ $77.00
8/12/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$81.00 ➝ $83.00
8/7/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$20.00 ➝ $22.00
8/7/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$57.00 ➝ $56.00
8/7/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$80.00 ➝ $100.00
8/6/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$119.00 ➝ $120.00
8/6/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$130.00 ➝ $135.00
8/5/2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$100.00 ➝ $109.00
8/4/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$196.54M10.30N/AN/A$1.35 per share12.51
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$627.24M10.99N/AN/A$5.70 per share6.58
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M586.30N/AN/A$13.47 per share2.70
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
$130.13M49.82N/AN/A$0.35 per share278.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$140.04M-$0.75N/AN/AN/A-35.40%-62.62%-25.16%11/5/2025 (Estimated)
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$177.03M-$0.88N/AN/AN/A-40.83%-32.00%-20.07%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$600.09M-$4.50N/AN/AN/AN/A-41.78%-35.63%11/5/2025 (Estimated)
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$260.60M-$3.01N/AN/AN/A-117.13%-1,831.43%-48.33%11/4/2025 (Estimated)

Latest ARQT, LEGN, RVMD, and RYTM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$0.22-$0.34-$0.12-$0.34$237.49 million$255.06 million
8/6/2025Q2 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.18-$0.13+$0.05-$0.13$72.70 million$81.50 million
8/6/2025Q2 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$0.94-$1.31-$0.37-$1.31$0.50 millionN/A
8/5/2025Q2 2025
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
-$0.66-$0.75-$0.09-$0.75$43.72 million$48.50 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.77
3.20
3.04
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.30
4.71
4.57
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.13
11.79
11.79
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
2.79
2.64

Institutional Ownership

CompanyInstitutional Ownership
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
70.89%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150119.90 million108.63 millionOptionable
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2,609183.76 million183.73 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.93 million171.60 millionOptionable
Rhythm Pharmaceuticals, Inc. stock logo
RYTM
Rhythm Pharmaceuticals
14066.42 million62.37 millionOptionable

Recent News About These Companies

Leerink Partnrs Has Positive Outlook of RYTM Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$16.89 +0.91 (+5.69%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$16.76 -0.13 (-0.74%)
As of 04:51 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$37.50 -0.21 (-0.56%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$37.63 +0.13 (+0.35%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$36.32 +0.30 (+0.83%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$36.32 0.00 (0.00%)
As of 08/15/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Rhythm Pharmaceuticals stock logo

Rhythm Pharmaceuticals NASDAQ:RYTM

$97.61 +1.13 (+1.17%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$95.50 -2.11 (-2.16%)
As of 04:52 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.